VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Tanyi Describes a Novel Two-Step Immunotherapy

Janos L. Tanyi, MD, PhD
Published: Thursday, May 02, 2013

Janos L. Tanyi, MD, PhD, an Assistant Professor of Obstetrics and Gynecology in the Division of Gynecologic Oncology at the University of Pennsylvania, discusses two phase I studies that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Two studies found clinically beneficial responses for a novel two-step dendritic cell vaccination and adoptive T-cell therapy for women with stage 3 and 4 ovarian cancer. Traditionally, Tanyi notes, the response rate for these patients, when receiving second-line chemotherapy, is between 15% and 30%. However, in these studies, 61% of the 31 patients enrolled experienced a clinical benefit with the vaccine alone and 75% saw a clinical benefit when both treatments were administered.

At this time, Tanyi cautions, immunotherapy is not a cure for ovarian cancer but it is capable of controlling the disease. He notes this approach was tested in patients who received several prior therapies and, if further trials are successful, greater benefits may be demonstrated as a primary treatment for women with advanced ovarian cancer.

Janos L. Tanyi, MD, PhD, an Assistant Professor of Obstetrics and Gynecology in the Division of Gynecologic Oncology at the University of Pennsylvania, discusses two phase I studies that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Two studies found clinically beneficial responses for a novel two-step dendritic cell vaccination and adoptive T-cell therapy for women with stage 3 and 4 ovarian cancer. Traditionally, Tanyi notes, the response rate for these patients, when receiving second-line chemotherapy, is between 15% and 30%. However, in these studies, 61% of the 31 patients enrolled experienced a clinical benefit with the vaccine alone and 75% saw a clinical benefit when both treatments were administered.

At this time, Tanyi cautions, immunotherapy is not a cure for ovarian cancer but it is capable of controlling the disease. He notes this approach was tested in patients who received several prior therapies and, if further trials are successful, greater benefits may be demonstrated as a primary treatment for women with advanced ovarian cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x